Zdechlik was Founding member of the U.S. Clinical Molecular Diagnostic Group
NEW YORK, July 23 /PRNewswire-USNewswire/ -- Exosome Diagnostics, Inc., the developer of non-invasive molecular oncology diagnostics to aid in early cancer detection and therapeutic selection, announced today that Greg Zdechlik has been named Chief Operating Officer. As COO, Zdechlik will be responsible for driving diagnostic development, commercial relations, and product introduction including Exosome's new blood based EGFR, KRAS and BRAF assays.
"Greg brings considerable industry expertise to our operating team," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "His track record of developing and growing platform technologies, including Roche's highly successful PCR products, will help us navigate licensing and production of exosome non-invasive oncology assay."
Mr. Zdechlik, an in-vitro diagnostic industry veteran, has been with Roche Diagnostics for over 22 years, including 15 years in the clinical molecular diagnostics field. He served as a founding commercial team member of Roche Diagnostic's U.S. clinical molecular diagnostics group and has held executive level positions including sales management, corporate development and strategic marketing. His responsibilities included leading the effort to seek new technologies, evaluating new business opportunities for the U.S. diagnostic business, developing strategic investment and action plans to achieve U.S. market leadership for key Roche business platforms, directing efforts to ensure that clinical endpoints, clinical trial design, publication strategy, market development strategy, key opinion leader development and health economic strategy for high value technologies were aligned with the market needs to achieve peak product sales faster.
"This is one of the more exciting technologies I have seen in molecular diagnostics," said Zdechlik. "Exosome's technology has the potential to enable a series of companion and tumor profiling diagnostics which deliver valuable information for clinicians to precisely monitor cancer status and manage available therapies."
About Exosome Diagnostics
Exosome Diagnostics is a developer of proprietary molecular diagnostic tests with applications in oncology and metabolic disease. The company's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers that can be reliably harvested from blood and urine and used diagnostically. For more information, visit www.exosomedx.com.
SOURCE Exosome Diagnostics, Inc.